Tuesday, August 10, 2021 12:41:14 PM
And as to Nader Pourhassan Ph.D. the key driver of CytoDyn
I respect his humanity and his drive to do good - that will help even those that revile him. Isn't that ironic. His efforts to bring Leronlimab to market could well save or enhance the lives of those who spend soooooo much time trying to tear him down.
>>> As noted by others, the same almost word-for-word attacks are cast. To me. These attacks on CytoDyn and NP appear scripted. A few have the knowledge base to deviate from the script, but most are mindlessly repetitious.
Yet, NP ignores these constant attacks and "carries on."
He doesn't waste time responding, instead moves on relentlessly toward making Leronlimab available for the good of ALL of us, instead of allowing BP to gain control and the ability to parse LL out on their terms.
He cares about people and shows it as he springs to their aid.
We could use a lot more Naders in this world.
In the meantime I will do what I can to support him on this mission to bring us the freedom to employ Leronlimab to better our lives.
And I believe there is a sincere devoted core of others here that feel similarly.
I respect his humanity and his drive to do good - that will help even those that revile him. Isn't that ironic. His efforts to bring Leronlimab to market could well save or enhance the lives of those who spend soooooo much time trying to tear him down.
>>> As noted by others, the same almost word-for-word attacks are cast. To me. These attacks on CytoDyn and NP appear scripted. A few have the knowledge base to deviate from the script, but most are mindlessly repetitious.
Yet, NP ignores these constant attacks and "carries on."
He doesn't waste time responding, instead moves on relentlessly toward making Leronlimab available for the good of ALL of us, instead of allowing BP to gain control and the ability to parse LL out on their terms.
He cares about people and shows it as he springs to their aid.
We could use a lot more Naders in this world.
In the meantime I will do what I can to support him on this mission to bring us the freedom to employ Leronlimab to better our lives.
And I believe there is a sincere devoted core of others here that feel similarly.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
